Is there evidence to support the use of definitive CRT in patients with NSCLC in separate ipsilateral lobes and mediastinal lymph node involvement?   

Most trials establishing CRT as standard of care for IIIB NSCLC excluded patients with separate ipsilateral lung nodules given that they were categorized as M1 until AJCC 7ed. What would you recommend for these patients?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Michigan Medical School
I also agree with @Percy Lee's thoughtful answer. ...
Sign in or Register to read more